Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations

30 Mar 2010

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to RNA and protein synthesis mechanisms
Share to Viral Infections and Immunology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20409719
DOI: 10.1016/j.bmc.2010.03.060

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Repairing faulty genes by aminoglycosides: Development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutationsPMID 20409719Read ↗

Increased Selectivity toward Cytoplasmic versus Mitochondrial Ribosome Confers Improved Efficiency of Synthetic Aminoglycosides in Fixing Damaged Genes: A Strategy for Treatment of Genetic Diseases Caused by Nonsense MutationsSemantic proximity Read ↗

Aminoglycosides redesign strategies for improved antibiotics and compounds for treatment of human genetic diseases.Semantic proximity Read ↗

Pharmaceutical therapies to recode nonsense mutations in inherited diseasesSemantic proximity Read ↗

Pharmaceuticals Targeting Nonsense Mutations in Genetic DiseasesSemantic proximity Read ↗

Novel small molecules potentiate premature termination codon readthrough by aminoglycosides.Semantic proximity Read ↗

Development of Novel Aminoglycoside (NB54) with Reduced Toxicity and Enhanced Suppression of Disease-Causing Premature Stop MutationsSemantic proximity Read ↗

[Allele-specific therapy: suppression of nonsense mutations by readthrough inducers].Semantic proximity Read ↗

Aminoglycoside-mediated suppression of nonsensemutations in late infantile neuronal ceroid lipofuscinosisSemantic proximity Read ↗

ELX-02: an investigational read-through agent for the treatment of nonsense mutation-related genetic disease.Semantic proximity Read ↗

[Progress in genetic susceptibility to aminoglycoside-induced deafness].Semantic proximity Read ↗

Suppression of aminoglycoside-induced premature termination codon readthrough by the TRP channel inhibitor AC1903Semantic proximity Read ↗

Gentamicin B1 is a minor gentamicin component with major nonsense mutation suppression activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.